- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00334048
Treating Sexual Dysfunction From Selective Serotonin Reuptake Inhibitor (SSRI) Medication: a Study Comparing Requip CR to Placebo
Treatment of Sexual Dysfunction Secondary to Antidepressant Pharmacotherapy: A Double-blind Comparison of Requip (Ropinirole) vs. Placebo in Patients Taking SSRI Antidepressants
Study Overview
Detailed Description
A significant proportion of patients taking pharmacotherapy for treatment of depression experience sexual dysfunction at distressing levels, with reported rates varying considerably. When sexual dysfunction is assessed prospectively using structured questionnaires, high levels of dysfunction have been found. SSRIs including paroxetine, sertraline, and other medications, have been shown to have a similar frequency of sexual side effects and in a recent prospectively designed study 50% of men taking sertraline reported that they were only "slightly" (18%) or "not at all" (32%) satisfied with their sexual functioning. It is reported that sexual side effects of antidepressant treatment frequently result in noncompliance with and/or premature discontinuation of treatment. A recent study showed that the dopamine agonist Requip (Ropinirole) reduced the amount of SSRI-associated sexual dysfunction. The proposed study will utilize a placebo control group in a crossover design to determine the effect on sexual dysfunction of adding Requip (Requip CR formulation) to the patient's SSRI treatment.
30 patients experiencing sexual dysfunction attributable to SSRI treatment for depression will be entered into this study. All patients will receive 6 weeks of treatment with Ropinirole and 6 weeks with placebo in a crossover fashion. Assessments of sexual functioning and depression will be made at each visit.
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
New York
-
New York, New York, United States, 10019
- Mood Disorders Research Program
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- male or female outpatients 18-65 years old
- currently taking fluoxetine, sertraline, paroxetine, citalopram, or escitalopram at a stable dosage within the ranges specified for 1 month or longer required dosage range: (Prozac (fluoxetine) 20-80 mg/day; Celexa (citalopram) 20-60 mg/day; Lexapro (escitalopram) 10-30 mg/day; Zoloft (sertraline) 50-200 mg/day; Paxil (paroxetine) 20-60 mg/day; Paxil CR (paroxetine CR) 25-75 mg/day
Currently responding to the SSRI antidepressant treatment, as indicated by
- a score of 15 or less on the HDRS 24 item at screening and baseline, and (b) CGI-Severity score of 2 or less at baseline
- Meets DSM-IV criteria for Substance-Induced Sexual Dysfunction, with impairment of desire, arousal, or orgasm
- Are currently involved in an intimate relationship which includes sexual contact
- agree to use double-barrier contraception during sexual intercourse during the course of the study (women only)
- Agree to the study team contacting the physician who prescribe their SSRI medication to inform them of their participation in the current study
Exclusion Criteria:
- Patients with a DSM-IV diagnosis of Delirium, Dementia, and Amnestic, and other Cognitive Disorders,
- Patients with a principal diagnosis meeting DSM-IV criteria for: Bipolar Disorder or cyclothymia, Schizophrenia, Delusional (Paranoid) Disorders and Psychotic Disorders Not Otherwise Specified, or Anorexia Nervosa or Bulimia,
- Patients who, within the past 6 months, met DSM-IV criteria for abuse of or dependence on any drug, including alcohol,
Patients who would pose a serious risk for suicide during the course of the study, as evidenced by one of the following:
- report of having a specific plan for killing themselves,
- a score of 3 or higher on the Hamilton Depression Rating Scale item 3 as rated by the study doctor at the first visit, (indicative of active suicidal thoughts or behaviors), or
- a suicide attempt within the past 6 months,
- Patients with a history of medical conditions or procedures which may cause sexual dysfunction, including: peripheral vascular disease, radical prostatectomy, trans-urethral resection of the prostate [TURP], or spinal cord injury.
- History of sexual dysfunction predating onset of depression and/or initiation of antidepressant therapy,
- Patients receiving any other treatment for sexual dysfunction, including sex therapy
- Pregnant or nursing women.
- Patients with unstable or life-threatening medical conditions, such as uncontrolled hypertension, diabetes, or hypothyroidism, acute infections, pneumonia, severe renal or hepatic impairment.
- Patients with any the following: retinal disease, sleep apnea, or narcolepsy.
- Patients taking dopamine agonist medication.
Patients taking medications that are
- associated with orthostatic hypotension, such as tricyclic antidepressants, MAO Inhibitors, and alpha1 antagonists
- CYP1A2 inhibitors, such as fluoroquinolones, fluvoxamine, cimetidine
- SSRI medication used cyclically for PMDD
- Patients who do not expect to have regular sexual contact with another person over the next 13 weeks.
- Patients with a DSM-IV diagnosis of Pathological Gambling
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
International Index of Erectile Function (IIEF)
Time Frame: 6 weeks
|
6 weeks
|
Sexual Function and Satisfaction Questionnaire (SFSQ)
Time Frame: 6 weeks
|
6 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Hamilton Depression Rating Scale, 17 items (HDRS-17)
Time Frame: 6 weeks
|
6 weeks
|
Global Assessment of Functioning Scale (GAFS)
Time Frame: 6 weeks
|
6 weeks
|
Clinical Global Impressions (CGI)
Time Frame: 6 weeks
|
6 weeks
|
CGI-Sexual functioning (CGI-Sx)
Time Frame: 6 weeks
|
6 weeks
|
Collaborators and Investigators
Collaborators
Investigators
- Principal Investigator: David J. Hellerstein, MD, St. Luke's Roosevelt Hospital Center and NY State Psychiatric Institute
Publications and helpful links
General Publications
- Worthington JJ 3rd, Simon NM, Korbly NB, Perlis RH, Pollack MH; Anxiety Disorders Research Program. Ropinirole for antidepressant-induced sexual dysfunction. Int Clin Psychopharmacol. 2002 Nov;17(6):307-10. doi: 10.1097/00004850-200211000-00006.
- Balon R. Sexual function and dysfunction during treatment with psychotropic medications. J Clin Psychiatry. 2005 Nov;66(11):1488-9. doi: 10.4088/jcp.v66n1120. No abstract available.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 06-036
- NYSPI IRB# 5185
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Sexual Dysfunction
-
Istanbul University - Cerrahpasa (IUC)CompletedSexual Dysfunction | Pregnancy Related | Postpartum Sexual DysfunctionTurkey
-
BayerCompletedSexual Dysfunction | Male Erectile DysfunctionBelgium, Italy, France, Germany, Spain, Netherlands, South Africa
-
Cairo UniversityCompleted
-
Alza Corporation, DE, USACompletedSexual Dysfunction | Erectile Dysfunction | Ejaculation
-
Johnson & Johnson Pharmaceutical Research & Development...CompletedSexual Dysfunction | Erectile DysfunctionFrance, Poland, United States, Belgium, Mexico, Malaysia, Canada, Taiwan, Korea, Republic of, Russian Federation, Argentina, Australia, United Kingdom
-
Royal Holloway UniversityNational Health Service, United KingdomCompletedSexual Dysfunction | Sexual Assault | Sex DisorderUnited Kingdom
-
Man Clinic for Andrology, Male Infertility and...UnknownSexual Dysfunction | Erectile Dysfunction | Premature EjaculationEgypt
-
University of UtahAcerus Pharmaceuticals CorporationWithdrawnSexual Dysfunction | Erectile DysfunctionUnited States
-
Assiut UniversityNot yet recruitingSexual Dysfunction
Clinical Trials on Ropinirole (Requip)
-
Lupin Ltd.CompletedPharmacokinetic StudyIndia
-
Titan PharmaceuticalsTerminatedParkinson DiseaseUnited States
-
Seoul National University HospitalCompletedParkinson DiseaseKorea, Republic of
-
GlaxoSmithKlineCompletedParkinson's Disease | Parkinson Disease | DyskinesiasUnited States
-
Teva Pharmaceuticals USACompleted
-
Dr. Reddy's Laboratories LimitedCompleted
-
Rajesh Pahwa, MDGlaxoSmithKlineCompleted
-
Teva Pharmaceuticals USACompleted